Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T M Hackeng

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Thrombosis and Haemostasis|November 1, 1994
Construction and characterization of thrombin-resistant variants of recombinant human protein SG T Chang, L Aaldering, T M Hackeng, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 22, 1997
Total chemical synthesis of enzymatically active human type II secretory phospholipase A2T M Hackeng, C M Mounier, C Bon, et al.
The Biochemical Journal|October 15, 1996
Protein C activation on endothelial cells by prothrombin activation products generated in situ: meizothrombin is a better protein C activator than alpha-thrombinT M Hackeng, G Tans, S J Koppelman, et al.
Journal of Thrombosis and Haemostasis : JTH|January 26, 2013
Direct inhibition of factor VIIa by TFPI and TFPI constructsS Peraramelli, S Thomassen, A Heinzmann, et al.
FEBS Letters|February 15, 1993
The region Ser333-Arg356 of the alpha-chain of human C4b-binding protein is involved in the binding of complement C4bM Hessing, D Kanters, H Takeya, et al.
Journal of Thrombosis and Haemostasis : JTH|February 18, 2017
New functional assays to selectively quantify the activated protein C- and tissue factor pathway inhibitor-cofactor activities of protein S in plasmaN A Alshaikh, J Rosing, M C L G D Thomassen, et al.
The Journal of Biological Chemistry|April 25, 2000
Inactivation of active thrombin-activable fibrinolysis inhibitor takes place by a process that involves conformational instability rather than proteolytic cleavageP F Marx, T M Hackeng, P E Dawson, et al.
Thrombosis and Haemostasis|July 1, 1995
Activated protein C resistance: molecular mechanismsJ H Griffin, M J Heeb, Y Kojima, et al.
Blood|May 15, 1993
Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism?J D Oosting, R H Derksen, I W Bobbink, et al.
Journal of Thrombosis and Haemostasis : JTH|October 22, 2010
CXCL4L1 inhibits angiogenesis and induces undirected endothelial cell migration without affecting endothelial cell proliferation and monocyte recruitmentA Sarabi, B K Kramp, M Drechsler, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Thrombosis and Haemostasis|November 1, 1994
Construction and characterization of thrombin-resistant variants of recombinant human protein SG T Chang, L Aaldering, T M Hackeng, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 22, 1997
Total chemical synthesis of enzymatically active human type II secretory phospholipase A2T M Hackeng, C M Mounier, C Bon, et al.
The Biochemical Journal|October 15, 1996
Protein C activation on endothelial cells by prothrombin activation products generated in situ: meizothrombin is a better protein C activator than alpha-thrombinT M Hackeng, G Tans, S J Koppelman, et al.
Journal of Thrombosis and Haemostasis : JTH|January 26, 2013
Direct inhibition of factor VIIa by TFPI and TFPI constructsS Peraramelli, S Thomassen, A Heinzmann, et al.
FEBS Letters|February 15, 1993
The region Ser333-Arg356 of the alpha-chain of human C4b-binding protein is involved in the binding of complement C4bM Hessing, D Kanters, H Takeya, et al.
Journal of Thrombosis and Haemostasis : JTH|February 18, 2017
New functional assays to selectively quantify the activated protein C- and tissue factor pathway inhibitor-cofactor activities of protein S in plasmaN A Alshaikh, J Rosing, M C L G D Thomassen, et al.
The Journal of Biological Chemistry|April 25, 2000
Inactivation of active thrombin-activable fibrinolysis inhibitor takes place by a process that involves conformational instability rather than proteolytic cleavageP F Marx, T M Hackeng, P E Dawson, et al.
Thrombosis and Haemostasis|July 1, 1995
Activated protein C resistance: molecular mechanismsJ H Griffin, M J Heeb, Y Kojima, et al.
Blood|May 15, 1993
Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism?J D Oosting, R H Derksen, I W Bobbink, et al.
Journal of Thrombosis and Haemostasis : JTH|October 22, 2010
CXCL4L1 inhibits angiogenesis and induces undirected endothelial cell migration without affecting endothelial cell proliferation and monocyte recruitmentA Sarabi, B K Kramp, M Drechsler, et al.
Pageof 6